Replimune Group, Inc. Class Action Lawsuit - REPL

The filed complaint alleges that Replimune Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

In order to be eligible to join the REPL class action lawsuit, you must have incurred a loss on shares of Replimune Group, Inc. purchased during the class period listed above.

If you suffered a loss in Replimune Group, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until September 22, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.